---
document_datetime: 2025-03-03 13:53:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/litfulo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: litfulo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.6299293
conversion_datetime: 2025-12-27 17:41:04.208825
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Litfulo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0007              | Update of section 4.8 of the SmPC in order to update the safety information based on interim results from study B7981032 listed as a category 3 study in the RMP; this is a phase 3 open-label, multi-center, long- term study investigating the safety and efficacy of ritlecitinib in adult and adolescent participants with | 13/02/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | alopecia areata. The RMP version 2 is acceptable. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                          |            |     |                       |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|-----------------------------------|
| PSUSA/133/2 02406 | Periodic Safety Update EU Single assessment - ritlecitinib                                                                                                                                                                                   | 16/01/2025 | n/a |                       | PRAC Recommendation - maintenance |
| IB/0006           | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                    | 11/10/2024 |     | SmPC                  |                                   |
| IA/0004           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 28/08/2024 | n/a |                       |                                   |
| PSUSA/133/2 02312 | Periodic Safety Update EU Single assessment - ritlecitinib                                                                                                                                                                                   | 11/07/2024 | n/a |                       | PRAC Recommendation - maintenance |
| IAIN/0003         | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                   | 05/06/2024 |     | SmPC, Annex II and PL |                                   |
| IB/0001           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 27/03/2024 |     | SmPC and Labelling    |                                   |